5418-10-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine is used as an anti-cancer agent for its ability to inhibit the growth of tumor cells. It has shown promising results in preclinical studies, making it a potential candidate for further research and development in cancer treatment.
Used in Research and Development:
4-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine is used as a valuable tool for studying signal transduction pathways. Its structure and properties allow researchers to gain insights into the mechanisms of action and develop targeted therapies for various diseases.
Used in Drug Discovery:
4-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine is used in drug discovery for its potential in treating other diseases such as cardiovascular and inflammatory conditions. Its pharmacological properties and inhibitory effects on certain kinases make it a promising candidate for the development of new therapeutic agents.

InChI:InChI=1/C6H6N4S/c1-11-6-4-2-9-10-5(4)7-3-8-6/h2-3H,1H3,(H,7,8,9,10)

Upstream product

• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 5188-07-8 sodium thiomethoxide 
• 5334-23-6 tisopurine 
• 74-88-4 methyl iodide 
• 315-30-0 Allopurinol 
• 5334-23-6 4-Mercapto-1H-pyrazolo<3,4-d>pyrimidine 

Downstream Products

• 1309377-73-8 C₁₃H₈FN₅S 
• 1309386-98-8 C₂₄H₂₅FN₆O₄ 
• 1309377-75-0 C₂₄H₂₅FN₆O₄ 
• 1309377-74-9 C₁₃H₈FN₅O₂S 
• 1192853-67-0 C₂₆H₃₂N₄O₃S 
• 1192853-65-8 C₂₆H₃₂N₄O₃S 
• 128059-89-2 1-<(2-benzyloxy-1-benzyloxymethylethoxy)methyl>-4(5H)-oxopyrazolo<3,4-d>pyrimidine 
• 128059-87-0 4-amino-1-<(2-benzyloxy-1-benzyloxymethylethoxy)methyl>pyrazolo<3,4-d>pyrimidine 
• 192369-82-7 Benzoic acid 1-acetoxymethyl-2-(4-methylsulfanyl-pyrazolo[3,4-d]pyrimidin-1-ylmethoxy)-ethyl ester 
• 142981-88-2 2-<2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl>-4-methylthio-1H-pyrazole<3,4-d>pyrimidine 
• 142981-84-8 1-<2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl>-4-methylthio-1H-pyrazole<3,4-d>pyrimidine 
• 142981-87-1 1-<2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl>-4-methylthio-1H-pyrazole<3,4-d>pyrimidine 
• 142981-85-9 2-<2-deoxy-3,5-di-O-(p-toluoyl)-δ-D-erythro-pentofuranosyl>-4-methylthio-1H-pyrazole<3,4-d>pyrimidine 
• 128059-86-9 1-<(2-benzyloxy-1-benzyloxymethylethoxy)methyl>-4-methylthiopyrazolo<3,4-d>pyrimidine 

Relevant academic research and scientific papers

FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Fused Bicyclic Pyrimidine Derivatives, compositions comprising a Fused Bicyclic Pyrimidine Derivative, and methods of using the Fused Bicyclic Pyrimidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.

NITROGENOUS FUSED BICYCLIC COMPOUND

A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)

Tricyclic base analogues

Nucleoside analogues have structure (2) wherein Q is H or a sugar moiety or sugar analogue or a modified sugar or a nucleic backbone or backbone analogue, W is an alkylene or alkenylene chain of 0-5 carbon atoms, any of which may carry a substituent R8, X is O or N or NR12or CR10, X′ is O or S or N, provided that when X′ is O or S, then X is C, Y is CH or N, R6is NH2or SMe or SO2Me or NHNH2, each of R7and R8is independently H or F or alkyl or alkenyl or aryl or acyl or a reporter moiety, R12is independently H or alkyl or alkenyl or aryl or acyl or a reporter moiety, and R10is H or ═O or F or alkyl or aryl or a reporter moiety.

Synthesis and biological activity of 4-substituted 1-[1-(2-hydroxyethoxy)-methyl-1,2,3-triazol-(4 & 5)-Ylmethyl]-1H-pyrazolo[3,4-d]pyrimidines

The chemical synthesis of some 4-substituted 1-[1-(2-hydroxyethoxy)-methyl-1,2,3-triazol-(4 and 5)-ylmethyl]-1H-pyrazolo[3,4-d]pyrimidines 12a,b, 13a,b and 14-23 as acyclic nucleosides is described. Treatment of (2-acetoxyethoxy)methylbromide with sodium azide afforded (2-acetoxyethoxy)methylazide 9. The heterocycles 6a,b were alkylated, separately, with propargyl bromide to obtain, regioselectively, 4-(methyl and benzyl)thio-1-(prop-2-ynyl)-1H-pyrazolo[3,4-d] pyrimidines 7a,b. These N1alkylated products were condensed with compound 9 via a 1,3-dipolar cycloaddition reaction to obtain, after separation and deprotection, 1,4-and 1,5-regioisomers 12a,b and 13a,b. The deprotected acyclic nucleosides 12a and 13a served as precursors for the preparation of 4-amino (14 and 15), 4-methylamino (16 and 17), 4-benzylamino (18 and 19), 4-methoxy (20 and 21) and 4-hydroxy (22 and 23) analogues. Compounds 7a,b and all deprotected acyclic nucleosides were evaluated for their inhibitory effects against the replication of HIV-1(IIIB) and HIV-2(ROD) in MT-4 cells and for their anti-tumor activity. No marked activity was found. However, initial evaluation of 6a,b, 7a,b, 12a,b, 13a,b and 14-23 showed that compound 7b has marked activity against M. tuberculosis.